Breakthrough Antibiotic Exblifeb Receives Nod from European Medicines Agency

1 Feb 2024 , 11:11 AM

The antibiotic Exblifeb, developed by Chennai-based Orchid Pharma, is a major breakthrough as it contains Enmetazobactam, the first entirely Indian-developed beta lactamase inhibitor.

This ground-breaking medication became the first to achieve this stage of clinical development when it was recommended for marketing authorization by the European Medicines Agency (EMA) recently. The medication was invented in India.

‘Exblifeb’, created to combat the worldwide problem of Anti-Microbial Resistance (AMR), shows exceptional effectiveness in treating pneumonia, bacteremia, and complex urinary tract infections (cUTI) brought on by organisms that produce Extended Spectrum Beta-lactamases.

‘Exblifeb’ performed better in clinical studies than Piperacillin + Tazobactam, the standard medication. It is marketed as a strong, reasonably priced, and carbapenem-sparing medication that provides a workable way to combat the growing AMR epidemic.

This accomplishment not only establishes ‘Exblifeb’ as a leader in the fight against AMR, but it also emphasises how urgently practical solutions are needed. 

Orchid created enmetazobactam in India, and Allecra Therapeutics, a company based in the US, was granted an outlicense to continue developing it.

For feedback and suggestions, write to us at [e-mail]